Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Lymphoblastic Leukemia: early-phase trial registry

4 of 7 indexed Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Lymphoblastic Leukemia: 7 US clinical trials tracked, 4 recruiting.

Lymphoblastic Leukemia is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is University of Chicago, running 2 of these trials.

Enrollment posture brief

Registry condition lymphoblastic-leukemia

OPEN 4 | RECR 57% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Lymphoblastic Leukemia (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Lymphoblastic Leukemia

Lymphoblastic Leukemia lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphoblastic Leukemia is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Lymphoblastic Leukemia research.

    University of Chicago accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Lymphoblastic Leukemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 25 among the 7 trials that report a genuine target (sentinel values excluded). 7 of those (100%) plan for fewer than 100 participants.

  4. Lymphoblastic Leukemia research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 23

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3

Named interventions

Most-linked intervention names on Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dexamethasone Drug
3 trials
Methotrexate Drug
2 trials
Dasatinib Drug
2 trials
Vincristine Drug
2 trials
Antithymocyte globulin Drug
1 trials
BEAM-201 Biological
1 trials
Inotuzumab ozogamicin Drug
1 trials
LP-118 Drug
1 trials

US sites by state

Facility locations filed on Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.

California 4 trials
Pennsylvania 3 trials
Illinois 3 trials
Texas 2 trials
Tennessee 2 trials
Oregon 2 trials
New York 2 trials
Massachusetts 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphoblastic Leukemia page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoblastic Leukemia condition card totals 7 registered trials; most-linked intervention Dexamethasone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.